Correlation Between Virax Biolabs and Corbus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and Corbus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and Corbus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virax Biolabs Group and Corbus Pharmaceuticals Holding, you can compare the effects of market volatilities on Virax Biolabs and Corbus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of Corbus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and Corbus Pharmaceuticals.

Diversification Opportunities for Virax Biolabs and Corbus Pharmaceuticals

-0.39

Correlation Coefficient

Virax Biolabs  Corbus Pharmaceuticals

Very good diversification

The 3 months correlation between Virax and Corbus is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and Corbus Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corbus Pharmaceuticals and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with Corbus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corbus Pharmaceuticals has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and Corbus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Virax Biolabs and Corbus Pharmaceuticals

Given the investment horizon of 90 days Virax Biolabs Group is expected to under-perform the Corbus Pharmaceuticals. In addition to that, Virax Biolabs is 1.11 times more volatile than Corbus Pharmaceuticals Holding. It trades about -0.13 of its total potential returns per unit of risk. Corbus Pharmaceuticals Holding is currently generating about -0.05 per unit of volatility. If you would invest  3,799  in Corbus Pharmaceuticals Holding on January 31, 2024 and sell it today you would lose (235.00) from holding Corbus Pharmaceuticals Holding or give up 6.19% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Virax Biolabs Group  vs.  Corbus Pharmaceuticals Holding

Virax Biolabs Group

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Corbus Pharmaceuticals

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Corbus Pharmaceuticals Holding are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady fundamental drivers, Corbus Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Virax Biolabs and Corbus Pharmaceuticals

The main advantage of trading using opposite Virax Biolabs and Corbus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, Corbus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will offset losses from the drop in Corbus Pharmaceuticals' long position.

The idea behind Virax Biolabs Group and Corbus Pharmaceuticals Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.